ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ironwood Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.87 times
2
With a growth in Net Profit of 25.8%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 185.56 MM
- INTEREST COVERAGE RATIO(Q) Highest at 1,107.37
- RAW MATERIAL COST(Y) Fallen by -0.15% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 207.19%, its profits have risen by 739% ; the PEG ratio of the company is 0
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 207.19% in the last 1 year, much higher than market (S&P 500) returns of 15.76%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Ironwood Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ironwood Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ironwood Pharmaceuticals, Inc.
205.84%
-0.34
101.53%
S&P 500
16.06%
1.20
13.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-5.33%
EBIT Growth (5y)
-5.59%
EBIT to Interest (avg)
12.02
Debt to EBITDA (avg)
1.99
Net Debt to Equity (avg)
-1.43
Sales to Capital Employed (avg)
1.17
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
82.56%
ROE (avg)
67.93%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
-1.91
EV to EBIT
7.34
EV to EBITDA
7.22
EV to Capital Employed
7.88
EV to Sales
2.94
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
107.34%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 185.56 MM
INTEREST COVERAGE RATIO(Q)
Highest at 1,107.37
RAW MATERIAL COST(Y)
Fallen by -0.15% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -196.33 %
NET SALES(Q)
At USD 113.04 MM has Grown at 25.08%
OPERATING PROFIT(Q)
Highest at USD 79.76 MM
OPERATING PROFIT MARGIN(Q)
Highest at 70.56 %
PRE-TAX PROFIT(Q)
Highest at USD 73.73 MM
NET PROFIT(Q)
Highest at USD 51.29 MM
EPS(Q)
Highest at USD 0.31
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Ironwood Pharmaceuticals, Inc.
Interest Coverage Ratio
Highest at 1,107.37
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Profit
At USD 51.29 MM has Grown at 96.23%
over average net sales of the previous four periods of USD 26.14 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 185.56 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 113.04 MM has Grown at 25.08%
over average net sales of the previous four periods of USD 90.38 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 79.76 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 70.56 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 73.73 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD 73.73 MM has Grown at 70.35%
over average net sales of the previous four periods of USD 43.28 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 51.29 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.31
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -196.33 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -0.15% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
